Search
Search Results
-
Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers
Background and ObjectiveTucatinib is a selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved to treat...
-
Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases
PurposeHER2-positive breast cancer has a high risk of brain metastasis. Stereotactic radiosurgery (SRS) is standard of care for limited brain...
-
The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
Background and ObjectiveTucatinib, a highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved for...
-
Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
Background and ObjectiveTucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer....
-
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15–20% of breast cancer cases. HER2 is a member of the...
-
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
PurposeTucatinib, a small molecule for the treatment of metastatic HER2-positive breast cancer, was extensively metabolized in humans to multiple...
-
Tucatinib: First Approval
Tucatinib is an oral, small molecule, selective HER2 inhibitor initially developed by Array BioPharma (a subsidiary of Pfizer) and subsequently...
-
-
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2+), conferring a particularly aggressive subtype of the...
-
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Approximately 15–20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2-directed...
-
HER2-Positive Metastatic Colorectal Cancer
Targeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2)–positive (amplified and/or overexpressed) metastatic...
-
Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases
In 2023, breast cancer brain metastases (BCBrM) remain a major clinical challenge gaining well-deserved attention. Historically managed with local...
-
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
HER2-positive breast cancer is an aggressive subtype of breast cancer with five-year survival rates of 30% for the advanced stage. The development of...
-
Das metastasierte Mammakarzinom – ein Überblick über die Therapiestandards
In metastatic breast cancer (MBC), interdisciplinary treatment concepts enable longer survival periods with good quality of life. The standard is...
-
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review
PurposeHuman epidermal growth factor receptor 2 (HER2)–targeted therapies improve survival for patients with HER2-positive breast cancer but carry...
-
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?
Breast cancer (BC) is the second most common tumour spreading to the central nervous system (CNS). The prognosis of patients with CNS metastases...
